Free Trial
NASDAQ:GRCE

Grace Therapeutics Q3 2025 Earnings Report

Grace Therapeutics logo
$2.97 +0.01 (+0.34%)
As of 08/6/2025 04:00 PM Eastern

Grace Therapeutics EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Grace Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grace Therapeutics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, February 12, 2025
Conference Call Time
6:00PM ET

Upcoming Earnings

Grace Therapeutics' Q1 2026 earnings is scheduled for Friday, August 8, 2025

Earnings Documents

Grace Therapeutics Earnings Headlines

GRCE: NDA Submitted
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Grace Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email.

About Grace Therapeutics

Grace Therapeutics (NASDAQ:GRCE) Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

View Grace Therapeutics Profile

More Earnings Resources from MarketBeat